The paradox between the beneficial intention of care and procedural pain highlights tensions relating to professional knowledge, denial attitudes and organizational deficiencies. Recognizing and assessing this pain category is critical for healthcare quality improvement. Current knowledge offers rich and effective preventive strategies. The multimodal approach incorporates the patient/caregiver relationship, non-pharmacological methods and preemptive analgesic administration. In this context, thanks to its properties and ease of use, EMONO (Equimolar Mixture of Oxygen and Nitrous Oxide) is a product worth knowing about and worth using, alone or in combination. Lifting the taboo and preventing procedural pain with patients is part of a process that can no longer be ignored.
Premature infants have somatic vulnerabilities that warrant specific monitoring and preventive measures in the first few months after leaving the neonatal unit. Their sensory and developmental vulnerabilities require also regular monitoring, at least until they reach the age of basic school learning. For very premature infants, coordinated monitoring is generally organized within a network for monitoring vulnerable children. Children with moderate prematurity also require special attention. Follow-up care for premature infants includes specific support for parents, who are often affected by the perinatal experience. They are the primary caregivers and developers of their children.
Cancer prognosis has steadily improved over recent decades. In 2025, approximately 85% of patients with cancer were in remission. The growing complexity of oncologic treatments has led to substantial gains in progression-free survival, albeit at the cost of increased cardiotoxic risk. Cardiotoxicity most commonly manifests as heart failure or left ventricular dysfunction. Consequently, the cardiovascular mortality of individuals treated for childhood cancers, as well as of older women treated for breast cancer, now equals or even exceeds oncologic mortality.In response, the European Society of Cardiology has issued its first cardio-oncology guidelines, establishing precise thresholds for left ventricular ejection fraction, longitudinal function (as assessed by echocardiographic strain parameters), and selected cardiac biomarkers. Within this framework, it is crucial to develop robust strategies to predict, enable early detection of, and ideally prevent treatment-related adverse cardiac effects. Rigorous control of traditional cardiovascular risk factors remains the cornerstone of preventing oncology-treatment-induced cardiotoxicity.
Long-term outcomes of preterm children are one of the major challenges in neonatology. Neurodevelopmental disorders are common in these children. Severe motor, cognitive or neurosensory disorders mainly affect the most immature children. Minor difficulties are present in more than a third of children, whatever their gestational age. School integration is frequently affected, and recourse to developmental support is important. A combination of certain factors should alert caregivers to the risk of neurodevelopmental disorders. These include male gender, small for gestational age, high-grade intraventricular hemorrhage, cystic periventricular leukomalacia or bronchopulmonary dysplasia. Early identification of neurodevelopmental disorders makes it possible to provide support for children and their families and to take advantage of the cerebral plasticity of the developing brain.
Sinonasal and petrous bone fungal infections are rare and life-threatening conditions that essentialy arise in immunocompromised patients. They are mainly due to Aspergillus in patients with hematological diseases and to Mucorales in diabetic. Invasive fungal sinusitis can be acute (invasive aspergillosis, rhino-orbito-cerebral mucormycosis) but chronic invasive sinusitis can also exist (invasive chronic fungal sinusitis and granulomatous invasive fungal sinusitis). Petrous bone fungal infections are similar to bacterial necrotizing otitis externa and are most often due to Aspergillus. The diagnosis must be made as early as possible with surgical biopsies, to allow early therapeutic management. Histopathological analysis is essential to confirm the diagnosis. The treatment is multidisciplinary and combines antifungal treatments with etiological care, sometimes associated with debridement surgery especially for mucormycosis.
